WO2010014836A3 - Modulateurs de tgr5 et leurs procédés d'utilisation - Google Patents

Modulateurs de tgr5 et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2010014836A3
WO2010014836A3 PCT/US2009/052290 US2009052290W WO2010014836A3 WO 2010014836 A3 WO2010014836 A3 WO 2010014836A3 US 2009052290 W US2009052290 W US 2009052290W WO 2010014836 A3 WO2010014836 A3 WO 2010014836A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tgr5 modulators
tgr5
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/052290
Other languages
English (en)
Other versions
WO2010014836A2 (fr
Inventor
Roberto Pellicciari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40433897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010014836(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP09791016.0A priority Critical patent/EP2324046B1/fr
Priority to AU2009276507A priority patent/AU2009276507B2/en
Priority to CN200980138550.7A priority patent/CN102164940B/zh
Priority to HK11112785.1A priority patent/HK1158212B/en
Priority to EA201170276A priority patent/EA020310B1/ru
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Priority to US13/056,797 priority patent/US8796249B2/en
Priority to BRPI0916735A priority patent/BRPI0916735B8/pt
Priority to CA2732323A priority patent/CA2732323C/fr
Publication of WO2010014836A2 publication Critical patent/WO2010014836A2/fr
Publication of WO2010014836A3 publication Critical patent/WO2010014836A3/fr
Anticipated expiration legal-status Critical
Priority to US14/449,995 priority patent/US9540414B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des composés de Formule A : (A) ou sur un sel, solvate ou hydrate de ceux-ci. Les composés de formule A sont des modulateurs de TGR5 utiles pour le traitement de maladies.
PCT/US2009/052290 2008-07-30 2009-07-30 Modulateurs de tgr5 et leurs procédés d'utilisation Ceased WO2010014836A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2732323A CA2732323C (fr) 2008-07-30 2009-07-30 Modulateurs de tgr5 et leurs procedes d'utilisation
BRPI0916735A BRPI0916735B8 (pt) 2008-07-30 2009-07-30 compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
CN200980138550.7A CN102164940B (zh) 2008-07-30 2009-07-30 Tgr5调节剂及其使用方法
HK11112785.1A HK1158212B (en) 2008-07-30 2009-07-30 Tgr5 modulators and methods of use thereof
EA201170276A EA020310B1 (ru) 2008-07-30 2009-07-30 Модуляторы рецептора tgr5 и их применение
EP09791016.0A EP2324046B1 (fr) 2008-07-30 2009-07-30 Modulateurs tgr5 et procédés d'utilisation correspondants
US13/056,797 US8796249B2 (en) 2008-07-30 2009-07-30 TGR5 modulators and methods of use thereof
AU2009276507A AU2009276507B2 (en) 2008-07-30 2009-07-30 TGR5 modulators and methods of use thereof
US14/449,995 US9540414B2 (en) 2008-07-30 2014-08-01 TGR5 modulators and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08013676.5 2008-07-30
EP08013676 2008-07-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/056,797 A-371-Of-International US8796249B2 (en) 2008-07-30 2009-07-30 TGR5 modulators and methods of use thereof
US14/449,995 Continuation US9540414B2 (en) 2008-07-30 2014-08-01 TGR5 modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2010014836A2 WO2010014836A2 (fr) 2010-02-04
WO2010014836A3 true WO2010014836A3 (fr) 2010-04-01

Family

ID=40433897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052290 Ceased WO2010014836A2 (fr) 2008-07-30 2009-07-30 Modulateurs de tgr5 et leurs procédés d'utilisation

Country Status (8)

Country Link
US (2) US8796249B2 (fr)
EP (1) EP2324046B1 (fr)
CN (2) CN105037476B (fr)
AU (1) AU2009276507B2 (fr)
BR (1) BRPI0916735B8 (fr)
CA (1) CA2732323C (fr)
EA (1) EA020310B1 (fr)
WO (1) WO2010014836A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10266560B2 (en) 2014-11-06 2019-04-23 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10457703B2 (en) 2015-03-31 2019-10-29 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575821B1 (fr) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire et satiogènes pour traitement du diabète, de l'obésité et d'états inflammatoires gastro-intestinaux
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (fr) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire pour traitement de l'hypercholemie et de la maladie cholestatique hepatique
SI3336097T1 (sl) 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
SG11201503247UA (en) * 2012-10-26 2015-06-29 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
WO2014200349A1 (fr) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Inhibiteur de la signalisation du cd40 et autre composé, l'autre composé étant un acide biliaire, un dérivé d'acide biliaire, un agoniste du récepteur tgr5, un agoniste du fxr ou une combinaison de ceux-ci, pour le traitement d'une inflammation chronique, et la prévention d'un cancer ou d'une fibrose gastro-intestinal(e)
BR112016002268B1 (pt) * 2013-08-01 2022-11-01 The Penn State Research Foundation Uso de inibidores do receptor x farnesoide
CA3236835A1 (fr) 2013-11-22 2015-05-28 Mina Therapeutics Limited Compositions d'arn a activation courte de c/ebp alpha et methodes d'utilisation
US10000527B2 (en) 2013-12-12 2018-06-19 Council Of Scientific And Industrial Research 11-substituted bile acid derivatives, process for the preparation thereof and use of these compounds as medicaments
SMT202000070T1 (it) * 2014-05-29 2020-03-13 Bar Pharmaceuticals S R L Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1
KR102546748B1 (ko) 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
EA033445B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
EP3223823A4 (fr) * 2014-11-26 2018-10-17 Enanta Pharmaceuticals, Inc. Analogues de l'acide biliaire utilisés comme agonistes de fxr/tgr5 et leurs procédés d'utilisation
EP3256134A4 (fr) 2015-02-11 2018-10-03 Enanta Pharmaceuticals, Inc. Analogues de l'acide biliaire utilisés comme agonistes de fxr/tgr5 et leurs procédés d'utilisation
US10800807B2 (en) 2015-06-19 2020-10-13 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA3075205A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions stabilisees de petits arn activateurs (parna) de hnf4a et procedes d'utilisation
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (fr) 2020-05-19 2021-11-25 Kallyope, Inc. Activateurs d'ampk
CA3183575A1 (fr) 2020-06-26 2021-12-30 Iyassu Sebhat Activateurs d'ampk
EP4623105A1 (fr) 2022-11-25 2025-10-01 Danmarks Tekniske Universitet Traitement d'échantillons de lait pour une analyse améliorée
WO2025054187A1 (fr) * 2023-09-05 2025-03-13 Sanford Burnham Prebys Medical Discovery Institute Antagonistes de tgr5 et procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002573A2 (fr) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
EP1947108A1 (fr) * 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. Modulateurs TGR5 et procédés d'utilisation correspondants
WO2008091540A2 (fr) * 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. Modulateurs de tgr5 et leurs procédés d'utilisation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3366932D1 (en) 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
ES2074113T3 (es) 1989-12-13 1995-09-01 Mitsubishi Chem Corp Nuevos derivados de acido pirazolil acrilico, utiles como fungicidas sistemicos para la proteccion de plantas y materiales.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP0921798A1 (fr) 1996-07-12 1999-06-16 Smithkline Beecham Plc Nouveau traitement contre la resistance a la leptine
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2318731C (fr) 1998-01-29 2012-05-29 Tularik Inc. Modulateurs du recepteur active de la proliferation des peroxysomes (ppar.gamma.)
WO2000025134A1 (fr) 1998-10-23 2000-05-04 Glaxo Group Limited Procede d'identification de ligands de recepteurs nucleaires
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
WO2000040965A1 (fr) 1999-01-07 2000-07-13 Tularik, Inc. Modulation du metabolisme du cholesterol induite par le recepteur fxr
AU780658B2 (en) 1999-03-26 2005-04-07 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
EP1473042B1 (fr) 1999-03-26 2006-06-21 City of Hope Criblage de composés modulant l'activité des récepteurs FXR
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CN1368884A (zh) 1999-06-11 2002-09-11 阿勒根销售公司 用于调节fxr受体活性的方法
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2386750A1 (fr) 1999-10-22 2001-05-03 Merck & Co. Inc. Medicaments destines au traitement de l'obesite
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
US7354726B2 (en) 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003015777A1 (fr) 2001-08-13 2003-02-27 Lion Bioscience Ag Composes de liaison au recepteur nucleaire nr1h4
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
WO2004048349A1 (fr) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Agonistes de recepteur farnesoide x
WO2005032549A1 (fr) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions et procedes pour traiter une fibrose
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
DK2698375T3 (en) 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002573A2 (fr) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
EP1947108A1 (fr) * 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. Modulateurs TGR5 et procédés d'utilisation correspondants
WO2008091540A2 (fr) * 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. Modulateurs de tgr5 et leurs procédés d'utilisation

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADV. BILE ACID RES., BILE ACID MEET., 3RD , MEETING DATE 1974, 105-7. EDITOR(S): MATERN, S.; HACKENSCHMIDT, J.; BACK, P. PUBLISHER: SCHATTAUER, STUTTGART, GER. CODEN: 37VJAK, 1975 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1978, HASLEWOOD, E. S. ET AL: "Specificity and some characteristics of a 7.alpha.-hydroxysteroid dehydrogenase from E. coli", XP002520346, retrieved from STN Database accession no. 1978:419015 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2000, SCHMIDER, W. ET AL: "Evidence for an additional sinusoidal bile salt transport system", XP002520345, retrieved from STN Database accession no. 2000:260886 *
FALK SYMPOSIUM , 108(BILE ACIDS AND CHOLESTASIS), 86-94 CODEN: FASYDI; ISSN: 0161-5580, 1999 *
FUKUCHI J ET AL: "5beta-Cholane activators of the farnesol X receptor", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 94, no. 4, 1 March 2005 (2005-03-01), pages 311 - 318, XP025298461, ISSN: 0960-0760, [retrieved on 20050301] *
KIHIRA, KENJI ET AL: "Synthesis of sulfonate analogs of bile acids", STEROIDS , 57(4), 193-8 CODEN: STEDAM; ISSN: 0039-128X, 1992, XP002520343 *
KIM H G ET AL: "Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters.", BIOLOGICAL & PHARMACEUTICAL BULLETIN MAR 2001, vol. 24, no. 3, March 2001 (2001-03-01), pages 218 - 220, XP002520340, ISSN: 0918-6158 *
MIKAMI, TAKAHIRO ET AL: "Effect of some sulfonate analogs of ursodeoxycholic acid on biliary lipid secretion in the rat", JOURNAL OF LIPID RESEARCH , 37(6), 1181-1188 CODEN: JLPRAW; ISSN: 0022-2275, 1996, XP002520341 *
MIKI, SHIGEO ET AL: "Sulfonate analogs of chenodeoxycholic acid: metabolism of sodium 3.alpha.,7.alpha.-dihydroxy-25-homo-5.beta.-cholane-25-sulfonate and sodium 3.alpha.,7.alpha.-dihydroxy-24-nor-5.beta.-cholane-23- sulfonate in the hamster", JOURNAL OF LIPID RESEARCH , 33(11), 1629-37 CODEN: JLPRAW; ISSN: 0022-2275, 1992, XP002520342 *
PELLICCIARI ROBERTO ET AL: "Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.", JOURNAL OF MEDICINAL CHEMISTRY 6 SEP 2007, vol. 50, no. 18, 6 September 2007 (2007-09-06), pages 4265 - 4268, XP002520344, ISSN: 0022-2623 *
SATO HIROYUKI ET AL: "Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.", JOURNAL OF MEDICINAL CHEMISTRY 27 MAR 2008, vol. 51, no. 6, 27 March 2008 (2008-03-27), pages 1831 - 1841, XP002520339, ISSN: 0022-2623 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266560B2 (en) 2014-11-06 2019-04-23 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10457703B2 (en) 2015-03-31 2019-10-29 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives

Also Published As

Publication number Publication date
HK1158212A1 (en) 2012-07-13
WO2010014836A2 (fr) 2010-02-04
US20110172198A1 (en) 2011-07-14
HK1217335A1 (zh) 2017-01-06
AU2009276507B2 (en) 2015-11-19
EP2324046B1 (fr) 2014-09-03
CA2732323A1 (fr) 2010-02-04
BRPI0916735B8 (pt) 2021-05-25
CA2732323C (fr) 2017-06-27
US8796249B2 (en) 2014-08-05
EP2324046A2 (fr) 2011-05-25
EA201170276A1 (ru) 2011-10-31
CN102164940B (zh) 2015-08-19
BRPI0916735B1 (pt) 2020-07-28
AU2009276507A1 (en) 2010-02-04
BRPI0916735A2 (pt) 2015-11-03
CN102164940A (zh) 2011-08-24
US9540414B2 (en) 2017-01-10
CN105037476A (zh) 2015-11-11
US20160052956A1 (en) 2016-02-25
EA020310B1 (ru) 2014-10-30
CN105037476B (zh) 2018-06-12

Similar Documents

Publication Publication Date Title
WO2010014836A3 (fr) Modulateurs de tgr5 et leurs procédés d'utilisation
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
IL205671A0 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2008083252A3 (fr) Procédés d'utilisation pour des analogues de cyclopamine
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
IL207570A0 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2006113919A3 (fr) Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
ZA200806510B (en) Heterobicyclic sulfonamide derivatives for the treatment of diabetes
WO2009156462A3 (fr) Composés organiques
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2225002A4 (fr) Interférence d'arn pour le traitement d'une insuffisance cardiaque
IL195571A0 (en) Compounds for the treatment of periodontal disease
IL190338A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2010129918A8 (fr) Promédicaments à base de triptolide
PT1948615E (pt) Derivados de pirazol úteis para o tratamento de doenças ginecológicas
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
WO2009124962A3 (fr) Sulfonamides
ZA200906462B (en) Hydrochloride salt of 5-[-3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2, 2-diphenylhexanamide
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
WO2008155666A3 (fr) Dérivés de pyrimidone hétéroarylamide
WO2008131946A3 (fr) Dérivés d'amide substitués
WO2009124733A8 (fr) Dérivés de sulfonamide substitués
EP1874283A4 (fr) Utilisation de nouveaux composes dans le traitement des maladies inflammatoires intestinales
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
HK1129328B (en) Alkoxy compounds for disease treatment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980138550.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09791016

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732323

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009276507

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009791016

Country of ref document: EP

Ref document number: 201170276

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2009276507

Country of ref document: AU

Date of ref document: 20090730

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13056797

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0916735

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110131